Professor Wafaa M. El-sadir from Columbia University gave a snapshot of the world of HIV prevention where she talked about the 3Ts (Trials, Travails and Triumphs) in the field. Over the past decades there has been an amazing evolution in the HIV epidemic from initially a deadly disease if not treated to now a chronic manageable condition with millions of people around the world living a healthy and productive life with HIV. which is a remarkable achievement in the HIV response.

There has been a remarkable progress over the past decades with prevention of new HIV infections. In 2017, there was 1.8 million new HIV infections. Despite the remarkable progress, it is highly unlikely that the world would be able to reach the goal of less than half a million new infections per year by 2020. This should compel us to think about how we can do better in terms of preventing new HIV infections.  This will include how we can better use the HIV prevention tools we have: antiretroviral therapy, prevention of horizontal transmission of HIV, and topical and systemic pre-exposure prophylaxis.  

Prof. Wafaa noted that there is a wealth of evidence that supports that ART + Viral suppression = prevention of HIV transmission. Some studies also show that prevention of new HIV infection in the population can be achieved by scaling up of ART prevention. Preventing new HIV infection in the population will require we identify everyone in the population, getting them tested, identify people who are HIV positive, place them on treatment by linking them to ART services, and secure and maintained the required support to enable people stay virally suppressed. Equal attention should be devoted to all the different stages of the HIV care continuum if we are to achieve our goal in decreasing the number of new HIV infections.

Several studies also shown that PrEP is highly protective but poor adherence is a risk factor for HIV acquisition while on PrEP with the impact worse for women. This had ignited interest in developing in long acting agents for HIV prevention such as the broadly neutralizing antibodies, long acting injectable ARVs, multipurpose rings as well as implants.

We are currently in the global era where combination and integrated services is critical to achieve the needed impact on new infections control.  All HIV management interventions proven effective need to integrated into a combination of HIV prevention strategies to achieve effectiveness. Without doing this, we will fail to achieve the potential of whatever new we discover. We also need precision intervention by learning about WHERE to focus (geographic area), WHO to focus on (specific population), HOW to focus (models of prevention) and also WHAT type of tools we would use for the identified population(s).

  • Alaka Oluwatosin